This trial is testing whether a high or low dose of cisplatin given with radiation therapy is better for treating a certain type of cancer.
- Head and Neck Cancer
3 Primary · 9 Secondary · Reporting Duration: Captured annually starting at a year post start of treatment and continued for up to 5 years following start of treatment.
2 Treatment Groups
ARM 1: High-Dose Cisplatin days 1, 22 & 43 with radiotherapy
1 of 2
ARM 2: Low-Dose Cisplatin Q 1 wk + radiotherapy
1 of 2
100 Total Participants · 2 Treatment Groups
Primary Treatment: ARM 1: High-Dose Cisplatin days 1, 22 & 43 with radiotherapy · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · All Participants · 11 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What objectives is this clinical research endeavor seeking to fulfill?
"The primary endpoint of this investigation over a 1-year time frame evaluates the prevalence of Grade 2 hearing loss. Secondary metrics being monitored include incidence of > grade 2 hearing loss, proportion of patients recommended for amplification and variations in Health related Quality Of Life (HRQOL) assessed using the EORTC QLQ-30 scale with scores ranging from 0 to 100 wherein higher values reflect increased response levels or quality of life." - Anonymous Online Contributor
How many participants are currently being accepted into this clinical experiment?
"Affirmative. Clinicaltrials.gov data affirms that this medical test, posted on November 5th 2018, is actively looking for participants. A total of 100 individuals are required from 3 separate research centres." - Anonymous Online Contributor
What is the objective of administering high-dose cisplatin on days 1, 22 & 43 in combination with radiotherapy?
"ARM 1: High-Dose Cisplatin administered on days 1, 22 & 43 combined with radiotherapy is a viable option for patients suffering from advanced ovarian cancer, advanced testicular cancer, and those who are unresponsive to traditional therapies." - Anonymous Online Contributor
Is there a current call for participants in this examination?
"Affirmative. Clinicaltrials.gov indicates that this clinical trial is actively recruiting, commencing on the 5th of November 2018 and last updated on the 7th of June 2022. The objective is to enrol 100 patients from 3 distinct medical facilities." - Anonymous Online Contributor
Has prior research indicated the efficacy of administering high-dose cisplatin on days 1, 22 and 43 in combination with radiotherapy for ARM 1?
"At present, 688 clinical trials examining ARM 1: High-Dose Cisplatin days 1, 22 & 43 with radiotherapy are taking place. Of these studies, 274 have reached the Phase 3 stage of their investigation. Shanghai is a major hub for such research; nonetheless, there are over forty thousand sites conducting tests related to this protocol worldwide." - Anonymous Online Contributor